文献速递其他结缔组织病

血清KL-6在肌炎相关间质性肺病管理中的价值

Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

该研究回顾2002-2017年新诊断PM、DM或临床无肌病性DM患者110例,其中75例(68%)合并ILD。基线血清KL-6在ILD组显著高于非ILD组(1120 vs 236 U/ml,P<0.001),且与复发相关,复发时KL-6显著升高(升高625 U/ml与复发相关)。结论认为血清KL-6是评估肌炎相关ILD疾病活动度的有用生物标志物。

要点

  • 基线血清KL-6在肌炎合并ILD组显著高于非ILD组(1120 vs 236 U/ml,P<0.001)。
  • 基线KL-6在诱导失败、复发、非复发三组间存在显著差异(1971 vs 1870 vs 935 U/ml,P=0.003)。
  • 复发时血清KL-6显著升高,升高625 U/ml与复发相关。

核心结论

  • 血清KL-6是评估肌炎相关间质性肺病疾病活动度的有用生物标志物。

研究设计与样本

  • 回顾性队列研究,纳入2002-2017年本机构新诊断的PM、DM或临床无肌病性DM连续患者110例。
  • 按有无ILD分为两组,ILD组再按临床病程分为诱导失败、复发和非复发三组。
  • 比较组间基线和时间进程中的参数变化。

主要发现

  • 110例入组患者中75例(68%)合并ILD。
  • 基线血清KL-6在ILD组显著高于非ILD组(1120 vs 236 U/ml;P<0.001)。
  • ILD组中诱导失败3例、复发24例、非复发48例,基线血清KL-6在三组间存在显著差异(1971 vs 1870 vs 935 U/ml;P=0.003,复发组 vs 非复发组)。
  • 血清KL-6的时间进程变化显示,KL-6随复发显著升高,升高625 U/ml与复发相关。

临床怎么用

  • 可将血清KL-6用于肌炎相关ILD的疾病活动度评估和复发监测。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify biomarkers for assessing myositis-associated interstitial lung disease (ILD). METHODS: We reviewed consecutive patients from our institution who had been newly diagnosed with PM, DM, or clinically amyopathic DM during the years 2002-2017. The patients were divided into two groups according to the presence of ILD, and the ILD group was further subdivided into three groups according to the clinical courses of induction failure, relapse and non-relapse. Baseline and time-course changes in the parameters were compared between groups. RESULTS: Among 110 patients enrolled, 75 (68%) had ILD. Baseline serum Krebs von den Lungen-6 (KL-6) was significantly higher in the ILD group than in the non-ILD group (1120 vs 236 U/ml; P < 0.001). In the ILD group consisting of the induction failure cases (n = 3), the relapse group (n = 24) and the non-relapse group (n = 48), baseline serum KL-6 was significantly different between the three groups [1971 vs 1870 vs 935 U/ml, respectively; P = 0.003 (relapse group vs non-relapse group)]. The time-course changes in serum KL-6 revealed that KL-6 significantly increased along with relapse, with the increase of 625 U/ml relevant to relapse. CONCLUSION: Serum KL-6 is a useful biomarker for assessing the disease activity of myositis-associated ILD.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Takanashi S, Nishina N, Nakazawa M, et al. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease. Rheumatology (Oxford). 2019. PMID: 30624752. doi:10.1093/rheumatology/key420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。